- Home
- AKRO vs GNTX Comparison
AKRO vs GNTX Comparison
Compare AKRO & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKRO
- GNTX
- Stock Information
- Founded
- AKRO 2017
- GNTX 1974
- Country
- AKRO United States
- GNTX United States
- Employees
- AKRO N/A
- GNTX N/A
- Industry
- AKRO Biotechnology: Pharmaceutical Preparations
- GNTX Auto Parts:O.E.M.
- Sector
- AKRO Health Care
- GNTX Consumer Discretionary
- Exchange
- AKRO Nasdaq
- GNTX Nasdaq
- Market Cap
- AKRO 4.5B
- GNTX 5.1B
- IPO Year
- AKRO 2019
- GNTX N/A
- Fundamental
- Price
- AKRO $54.34
- GNTX $22.23
- Analyst Decision
- AKRO Buy
- GNTX Buy
- Analyst Count
- AKRO 10
- GNTX 6
- Target Price
- AKRO $73.56
- GNTX $29.00
- AVG Volume (30 Days)
- AKRO 1.7M
- GNTX 3.2M
- Earning Date
- AKRO 11-07-2025
- GNTX 10-24-2025
- Dividend Yield
- AKRO N/A
- GNTX 2.15%
- EPS Growth
- AKRO N/A
- GNTX N/A
- EPS
- AKRO N/A
- GNTX 1.70
- Revenue
- AKRO N/A
- GNTX $2,431,504,922.00
- Revenue This Year
- AKRO N/A
- GNTX $11.92
- Revenue Next Year
- AKRO N/A
- GNTX $4.94
- P/E Ratio
- AKRO N/A
- GNTX $13.18
- Revenue Growth
- AKRO N/A
- GNTX 3.00
- 52 Week Low
- AKRO $21.34
- GNTX $20.28
- 52 Week High
- AKRO $58.40
- GNTX $31.41
- Technical
- Relative Strength Index (RSI)
- AKRO 68.92
- GNTX 23.43
- Support Level
- AKRO $54.10
- GNTX $23.00
- Resistance Level
- AKRO $54.37
- GNTX $23.68
- Average True Range (ATR)
- AKRO 0.18
- GNTX 0.47
- MACD
- AKRO -0.22
- GNTX -0.00
- Stochastic Oscillator
- AKRO 89.00
- GNTX 3.75
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
About GNTX Gentex Corporation
Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.